 "Wockhardt initiates phase-III clinical study of new antibiotic candidate")
Pharmaceutical firm Wockhardt Ltd on Tuesday said it has initiated a global Phase III clinical study of its new antibiotic candidate WCK 5222.
The company has completed the first site initiation visit for the study, Wockhardt said in a statement.
WCK 5222 is a drug, which is entirely a new class of antibiotic known as "-lactam ENHANCER, and is targeted for treatment of hospitalised adults with complicated urinary tract infections, including acute pyelonephritis, it added.
"WCK 5222 is a new class of antibiotic for gram-negative terrain for complicated urinary tract infections and hospital-acquired bacterial pneumonia (HABP/VABP)," Wockhardt Chairman Habil Khorakiwala said.
Scientific evidence clearly suggests WCK 5222, when available, will save many lives worldwide, he added.
The company said its study will have 70 centres worldwide in 11 countries, including the US, Europe, India, China and Latin America.
"This global study is expected to be completed in 18 months," it added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app